{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:12:38Z","timestamp":1789902758574,"version":"4.0.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Evidence for the efficacy of pharmacological therapies for heart failure with reduced ejection fraction (HFrEF) is growing. However, there is no consensus on the most effective treatment for HFrEF. This study aimed to evaluate the most effective combination of pharmacological therapy in patients with HFrEF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched Medline, Embase, and CENTRAL up to Feb 2022, to include randomized controlled trials (RCTs) that evaluated the efficacy of pharmacological treatment among adults (\u2265\u200918\u00a0years) with a diagnosis of HFrEF (defined by a left ventricular ejection fraction\u2009\u2264\u200945%). The outcomes of interest included all-cause death, cardiovascular (CV) death, and hospitalization for heart failure (HHF). A random network meta-analysis using a frequentist framework model was employed to calculate the pooled risk ratio (RR) with 95% confidence interval (CI) and rank the treatments.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We included 49 RCTs involving 90,529 participants with HFrEF. For reducing all-cause mortality, the combination of angiotensin-converting enzyme inhibitors (ACEI), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose co-transporter-2 inhibitors (SGLT2i) was most effective (RR, 0.46; 95% CI, 0.32\u20130.66). For CV death, the combination of ACEI, BB, MRA, and Vericiguat showed the highest efficacy (RR, 0.34; 95% CI, 0.12\u20130.90). Regarding reducing HHF, the combination of ACEI, BB, MRA, and SGLT2i as well as the combination of ACEI, BB, MRA, and Ivabradine were equally the most effective (both RR, 0.27; 95% CI, 0.18\u20130.39).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides robust evidence supporting the use of combination therapies in HFrEF management, with newer agents offering incremental benefits when added to established guideline-directed medical therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-04339-3","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T01:08:49Z","timestamp":1732324129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"24","author":[{"given":"Huilin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Germinal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Milfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Han","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hsuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingchuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"issue":"5","key":"4339_CR1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jama.2020.10262","volume":"324","author":"SP Murphy","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. 2020;324(5):488\u2013504.","journal-title":"JAMA"},{"issue":"1","key":"4339_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4\u201325.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"4339_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7\u201311.","journal-title":"Card Fail Rev"},{"issue":"1","key":"4339_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5152\/akd.2014.5731","volume":"15","author":"I Bytyci","year":"2015","unstructured":"Bytyci I, Bajraktari G. Mortality in heart failure patients. Anatol J Cardiol. 2015;15(1):63\u20138.","journal-title":"Anatol J Cardiol"},{"issue":"18","key":"4339_CR5","first-page":"e876","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e876\u201394.","journal-title":"Circulation"},{"issue":"10254","key":"4339_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819\u201329.","journal-title":"Lancet (London, England)"},{"issue":"21","key":"4339_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"4339_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"4339_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cjca.2021.01.017","volume":"37","author":"M McDonald","year":"2021","unstructured":"McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Heckman GA, Howlett JG, Koshman SL, Lepage S, et al. CCS\/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021;37(4):531\u201346.","journal-title":"Can J Cardiol"},{"issue":"11","key":"4339_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"11","key":"4339_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384.","journal-title":"Ann Intern Med"},{"key":"4339_CR12","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, Sterne AC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/22008217\/.","DOI":"10.1136\/bmj.d5928"},{"issue":"2","key":"4339_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","volume":"3","author":"IR White","year":"2012","unstructured":"White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111\u201325.","journal-title":"Res Synth Methods"},{"issue":"10","key":"4339_CR14","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS ONE. 2013;8(10):e76654.","journal-title":"PLoS ONE"},{"issue":"2","key":"4339_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.7326\/0003-4819-159-2-201307160-00008","volume":"159","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130\u20137.","journal-title":"Ann Intern Med"},{"issue":"3","key":"4339_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/bimj.201800167","volume":"62","author":"G Rucker","year":"2020","unstructured":"Rucker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. Biom J. 2020;62(3):808\u201321.","journal-title":"Biom J"},{"key":"4339_CR17","unstructured":"netcomb: Additive network meta-analysis for combinations of treatments [https:\/\/rdrr.io\/cran\/netmeta\/man\/netcomb.html]"},{"issue":"2","key":"4339_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397.","journal-title":"Res Synth Methods"},{"issue":"1","key":"4339_CR19","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dys222","volume":"42","author":"AA Veroniki","year":"2013","unstructured":"Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42(1):332\u201345.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"4339_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012;3(2):98\u2013110.","journal-title":"Res Synth Methods"},{"issue":"11","key":"4339_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"2","key":"4339_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synth Methods. 2012;3(2):161\u201376.","journal-title":"Res Synth Methods"},{"key":"4339_CR23","doi-asserted-by":"crossref","unstructured":"Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. The Captopril-Digoxin Multicenter Research Group. JAMA 1988, 259(4):539\u2013544.","DOI":"10.1001\/jama.259.4.539"},{"key":"4339_CR24","doi-asserted-by":"crossref","unstructured":"A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994, 90(4):1765\u20131773.","DOI":"10.1161\/01.CIR.90.4.1765"},{"key":"4339_CR25","doi-asserted-by":"crossref","unstructured":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England) 1999, 353(9146):9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"issue":"9169","key":"4339_CR26","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"Effect of metoprolol CR\/XL in chronic heart failure","year":"1999","unstructured":"Effect of metoprolol CR\/XL in chronic heart failure. Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999;353(9169):2001\u20137.","journal-title":"Lancet (London, England)"},{"key":"4339_CR27","doi-asserted-by":"crossref","unstructured":"Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. Circulation. 2000;101(4):378\u2013384.","DOI":"10.1161\/01.CIR.101.4.378"},{"issue":"20","key":"4339_CR28","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"7","key":"4339_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/j.1552-4604.1995.tb04107.x","volume":"35","author":"B Beller","year":"1995","unstructured":"Beller B, Bulle T, Bourge RC, Colfer H, Fowles RE, Giles TD, Grover J, Whipple JP, Fisher MB, Jessup M, et al. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. J Clin Pharmacol. 1995;35(7):673\u201380.","journal-title":"J Clin Pharmacol"},{"key":"4339_CR30","doi-asserted-by":"crossref","unstructured":"Beta-Blocker Evaluation of Survival Trial I, Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW: A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659\u20131667.","DOI":"10.1056\/NEJM200105313442202"},{"issue":"1","key":"4339_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","volume":"11","author":"A Boccanelli","year":"2009","unstructured":"Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di Lenarda A, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, et al. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009;11(1):68\u201376.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"4339_CR32","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","volume":"94","author":"MR Bristow","year":"1996","unstructured":"Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators Circulation. 1996;94(11):2807\u201316.","journal-title":"MOCHA Investigators Circulation"},{"issue":"8","key":"4339_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0002-9149(99)80624-9","volume":"75","author":"EJ Brown Jr","year":"1995","unstructured":"Brown EJ Jr, Chew PH, MacLean A, Gelperin K, Ilgenfritz JP, Blumenthal M. Effects of fosinopril on exercise tolerance and clinical deterioration in patients with chronic congestive heart failure not taking digitalis Fosinopril Heart Failure Study Group. Am J Cardiol. 1995;75(8):596\u2013600.","journal-title":"Am J Cardiol."},{"issue":"3","key":"4339_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1071-9164(97)90013-0","volume":"3","author":"JN Cohn","year":"1997","unstructured":"Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, et al. Safety and efficacy of carvedilol in severe heart failure The US Carvedilol Heart Failure Study Group. Journal of cardiac failure. 1997;3(3):173\u20139.","journal-title":"Journal of cardiac failure."},{"issue":"23","key":"4339_CR35","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. Valsartan Heart Failure Trial I: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667\u201375.","journal-title":"N Engl J Med"},{"issue":"11","key":"4339_CR36","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1161\/01.CIR.94.11.2800","volume":"94","author":"WS Colucci","year":"1996","unstructured":"Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure US Carvedilol Heart Failure Study Group. Circulation. 1996;94(11):2800\u20136.","journal-title":"Circulation"},{"issue":"9266","key":"4339_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","volume":"357","author":"HJ Dargie","year":"2001","unstructured":"Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (London, England). 2001;357(9266):1385\u201390.","journal-title":"Lancet (London, England)"},{"issue":"2\u20133","key":"4339_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0167-5273(00)00426-5","volume":"77","author":"PH Dunselman","year":"2001","unstructured":"Dunselman PH. Replacement of Angiotensin Converting Enzyme Inhibition I: Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. International journal of cardiology. 2001;77(2\u20133):131\u20138 discussion 139\u2013140.","journal-title":"International journal of cardiology"},{"issue":"12","key":"4339_CR39","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/oxfordjournals.eurheartj.a060844","volume":"16","author":"L Erhardt","year":"1995","unstructured":"Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure Fosinopril Efficacy\/Safety Trial (FEST) Study Group. Eur Heart J. 1995;16(12):1892\u20139.","journal-title":"Eur Heart J."},{"issue":"4","key":"4339_CR40","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/0735-1097(92)90529-V","volume":"19","author":"GC Fonarow","year":"1992","unstructured":"Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA, Moriguchi JD, Tillisch JH, Walden JA, Albanese E. Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll Cardiol. 1992;19(4):842\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"4339_CR41","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314(21):2251\u201362.","journal-title":"JAMA"},{"issue":"4","key":"4339_CR42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0002-8703(00)90037-1","volume":"139","author":"CB Granger","year":"2000","unstructured":"Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, Stevenson LW, Swedberg K, Young J, Yusuf S, et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000;139(4):609\u201317.","journal-title":"Am Heart J"},{"issue":"4","key":"4339_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ehf2.12042","volume":"2","author":"Z He","year":"2015","unstructured":"He Z, Sun Y, Gao H, Zhang J, Lu Y, Feng J, Su H, Zeng C, Lv A, Cheng K, et al. Efficacy and safety of supramaximal titrated inhibition of renin-angiotensin-aldosterone system in idiopathic dilated cardiomyopathy. ESC Heart Fail. 2015;2(4):129\u201338.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"4339_CR44","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ahj.2003.07.023","volume":"147","author":"M Hori","year":"2004","unstructured":"Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147(2):324\u201330.","journal-title":"Am Heart J"},{"issue":"5","key":"4339_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Investigators","year":"1991","unstructured":"Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med"},{"issue":"10","key":"4339_CR46","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Investigators","year":"1992","unstructured":"Investigators S, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685\u201391.","journal-title":"N Engl J Med"},{"issue":"4","key":"4339_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejheart.2003.12.019","volume":"6","author":"M Komajda","year":"2004","unstructured":"Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Ryden L, Scherhag A, et al. Tolerability of carvedilol and ACE-Inhibition in mild heart failure Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004;6(4):467\u201375.","journal-title":"Eur J Heart Fail."},{"issue":"9386","key":"4339_CR48","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","volume":"362","author":"JJ McMurray","year":"2003","unstructured":"McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, Investigators C, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (London, England). 2003;362(9386):767\u201371.","journal-title":"Lancet (London, England)"},{"issue":"21","key":"4339_CR49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","volume":"334","author":"M Packer","year":"1996","unstructured":"Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure U.S Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334(21):1349\u201355.","journal-title":"N Engl J Med."},{"issue":"22","key":"4339_CR50","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651\u20138.","journal-title":"N Engl J Med"},{"issue":"11","key":"4339_CR51","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1161\/01.CIR.94.11.2793","volume":"94","author":"M Packer","year":"1996","unstructured":"Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94(11):2793\u20139.","journal-title":"Circulation"},{"issue":"9215","key":"4339_CR52","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2013the Losartan Heart Failure Survival Study ELITE II. Lancet (London, England). 2000;355(9215):1582\u20137.","journal-title":"Lancet (London, England)"},{"issue":"14","key":"4339_CR53","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"9054","key":"4339_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","volume":"349","author":"B Pitt","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet (London, England). 1997;349(9054):747\u201352.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"4339_CR55","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med."},{"issue":"22","key":"4339_CR56","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1161\/01.CIR.100.22.2224","volume":"100","author":"GA Riegger","year":"1999","unstructured":"Riegger GA, Bouzo H, Petr P, Munz J, Spacek R, Pethig H, von Behren V, George M, Arens H. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999;100(22):2224\u201330.","journal-title":"Circulation."},{"issue":"4","key":"4339_CR57","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1388-9842(00)00120-3","volume":"2","author":"B Sturm","year":"2000","unstructured":"Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail. 2000;2(4):407\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"9744","key":"4339_CR58","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, Investigators S. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England). 2010;376(9744):875\u201385.","journal-title":"Lancet (London, England)"},{"issue":"20","key":"4339_CR59","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D\u2019Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"4339_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021;384(2):105\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"4339_CR61","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","volume":"82","author":"H Tsutsui","year":"2017","unstructured":"Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, Sunagawa K, Yasumura Y, Yano M, Yamamoto K, et al. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ J. 2017;82(1):148\u201358.","journal-title":"Circ J"},{"issue":"10","key":"4339_CR62","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Momomura SI, Yamashina A, Shimokawa H, Kihara Y, Saito Y, Hagiwara N, Ito H, Yano M, Yamamoto K, et al. Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study. Circ J. 2019;83(10):2049\u201360.","journal-title":"Circ J"},{"issue":"7","key":"4339_CR63","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0735-1097(98)00464-1","volume":"32","author":"DJ van Veldhuisen","year":"1998","unstructured":"van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man In TVAJ, Pinto YM, Lie KI, Crijns HJ. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32(7):1811\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"4339_CR64","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","volume":"380","author":"EJ Velazquez","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, Investigators P-H. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380(6):539\u201348.","journal-title":"N Engl J Med"},{"issue":"4","key":"4339_CR65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","volume":"347","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Nodari S, Caretta G, D\u2019Aloia A, Pezzali N, Faden G, Lombardi C, Raddino R, Metra M, Dei Cas L. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci. 2014;347(4):271\u20136.","journal-title":"Am J Med Sci"},{"issue":"1\u20132","key":"4339_CR66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF00192366","volume":"49","author":"J Widimsky","year":"1995","unstructured":"Widimsky J, Kremer HJ, Jerie P, Uhlir O. Czech and Slovak spirapril intervention study (CASSIS) A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure. Eur J Clin Pharmacol. 1995;49(1\u20132):95\u2013102.","journal-title":"Eur J Clin Pharmacol."},{"issue":"12","key":"4339_CR67","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0002-9149(00)00796-7","volume":"85","author":"S Witchitz","year":"2000","unstructured":"Witchitz S, Cohen-Solal A, Dartois N, Weisslinger N, Juste K, Darmon JY. Treatment of heart failure with celiprolol, a cardioselective beta blocker with beta-2 agonist vasodilatory properties. The CELICARD Group Am J Cardiol. 2000;85(12):1467\u201371.","journal-title":"The CELICARD Group Am J Cardiol"},{"issue":"1","key":"4339_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Group E-HS: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"4339_CR69","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","volume":"10","author":"J Tromp","year":"2022","unstructured":"Tromp J, Ouwerkerk W, van Veldhuisen DJ, Hillege HL, Richards AM, van der Meer P, Anand IS, Lam CSP, Voors AA. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022;10(2):73\u201384.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"4339_CR70","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/joim.13487","volume":"292","author":"V De Marzo","year":"2022","unstructured":"De Marzo V, Savarese G, Tricarico L, Hassan S, Iacoviello M, Porto I, Ameri P. Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. J Intern Med. 2022;292(2):333\u201349.","journal-title":"J Intern Med"},{"issue":"15","key":"4339_CR71","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","volume":"83","author":"TM Maddox","year":"2024","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Brouse S, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444\u201388.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4339_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14740\/cr991","volume":"11","author":"JI Sakamoto","year":"2020","unstructured":"Sakamoto JI, Shikata T, Ito S, Kimura T, Takamoto K, Manabe E, Asakura M, Ishihara M, Tsujino T. Polypharmacy Is Associated With Accelerated Deterioration of Renal Function in Cardiovascular Outpatients. Cardiol Res. 2020;11(1):15\u201321.","journal-title":"Cardiol Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04339-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:03:15Z","timestamp":1732366995000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04339-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4339"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04339-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"666"}}